quoting delegate and company name - Sachs Associates
quoting delegate and company name - Sachs Associates
quoting delegate and company name - Sachs Associates
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
EVENT SPONSORS<br />
www.investaustralia.gov.au<br />
www.katanassociates.com<br />
AnorMED<br />
www.anormed.com<br />
www.curis.com<br />
www.ecopiabio.com<br />
www.generex.com<br />
www.astrazeneca.com<br />
www.bioexec.com<br />
www.fr.com<br />
www.kl.com<br />
CORPORATE SPONSORS<br />
GLOBAL BIOTECH FORUM FOR<br />
www.isotis.com<br />
www.lifepointinc.com<br />
www.macrochem.com<br />
For Venture Capitalists, Fund Ma<br />
1 st -2 nd April 2004 • The Fair<br />
Biotechnology: From the Benchtop to the Boardroom<br />
The Key Steps for Early Stage Commercialization for Pre-Phase II Opportunities<br />
Pre-Conference Workshop: Wednesday 31st March 2004 14.30 – 18.30<br />
Led by: Stan Yakatan, Chairman & Seth Yakatan, Partner, Katan <strong>Associates</strong><br />
• John N. Vournakis, Ph.D., Vice President for Research <strong>and</strong> Development, Marine Polymer<br />
Technologies, Inc. <strong>and</strong> Professor of Graduate Studies at the Medical University of South Carolina<br />
This workshop provides a comprehensive framework for underst<strong>and</strong>ing & putting into practice<br />
the key elements to commercialization.<br />
For full workshop synopsis, please contact Pernilla Hellsten on +44 207 405 5544 or Pernilla@sachsforum.com<br />
Please see overleaf for registration details.<br />
T HURSDAY 1 ST A PRIL 2004<br />
7.45 Registration<br />
8.25 Chairman’s Welcome: P. Louis Myers, Ph.D., Principal, Fish & Richardson P.C.<br />
8.30 – Opening Panel: Venturing Financing Outlook for Biotech in 2004<br />
9.20 Chair: Michael Lytton, General Partner, Oxford Bioscience Partners<br />
• Jean M. George, Partner, Advanced Technology Ventures<br />
• Dr. Christoph H. Westphal, General Partner, Polaris Venture Partners<br />
• James M. Garvey, CEO & Managing Partner, Schroder Ventures Life Sciences<br />
• Ben Bronstein, Managing Director, Zero Stage Capital<br />
PRIVATE EQUITY AND THE LISTED MARKETS<br />
9.20 Stelios Papadopoulos, Ph.D., Vice Chairman, SG Cowen Securities Corporation<br />
9.40 – Panel: Capital Markets<br />
10.25 • Michael King, Managing Director, Healthcare Group, Bank of America<br />
• R. Nelson Campbell, Senior Vice President, Life Sciences Investment Banking,<br />
Friedman, Billings, Ramsey<br />
• Dr. Sam Fazeli, Senior Biotechnology Analyst, Nomura<br />
10.25 Break<br />
10.45 – Small-Cap/Listed Company Presentations<br />
12.45<br />
Chair: P. Louis Myers, Ph.D., Principal, Chair: Roger Feldman<br />
Fish & Richardson P.C. Fish & Richardson P.C<br />
AnorMed, Inc. IsoTis<br />
Curis, Inc. LifePoint, Inc.<br />
Ecopia BioSciences, Inc. MacroChem Corporation<br />
OPTIONAL<br />
WORKSHOP<br />
12.45<br />
Generex Biotechnology Corporation<br />
Lunch<br />
BIOPARTNERING & COLLABORATION<br />
14.00 – Panel: Evolving Pharma / Biotech Relationships<br />
14.50 Chair: Eileen Smith Ewing, Esq, Partner & Chair, Life Sciences Group,<br />
Kirkpatrick & Lockhart LLP<br />
• Dr. Maggie Flanagan, Global Alliance Director, Enabling Science, Technology <strong>and</strong><br />
Information, AstraZeneca Pharmaceuticals<br />
• Jan van Heek, Executive Vice President, Therapeutics & Genetics, Genzyme Corporation<br />
• Jeremy Levin, Global Head of Strategic Alliances,<br />
Novartis Institutes for Biomedical Research<br />
• Dr. Ravi Kiron, Global Head, Strategic Analysis & Knowledge Management Strategic<br />
Alliances, Pfizer Global R&D<br />
SECTOR WORKSHOPS: EARLY-STAGE COMPANY PRESENTATIONS<br />
15.00 – Workshop I: Workshop II: Workshop III:<br />
16.35 Immunology / Oncology<br />
Chair: Donna L. LaVoie,<br />
President & CEO,<br />
LaVoie Strategic<br />
Communications Group, Inc.<br />
Therapeutics Post-Genomics<br />
FUND OF FUNDS<br />
16.45– Panel: Fund of Funds<br />
17.30 Chair: William C. Mills III, Partner, Advent International<br />
• Matthew I. Hermann, Director, Strategic Health Venture Investing,<br />
Ascension Health Ventures<br />
• Gregory V. Stento, Managing Director, HarbourVest Partners LLC<br />
• Robert E. Mast, Managing Director, Monument Group<br />
• Otello Stampacchia Ph.D., Head of Life Sciences Investments, NIB Capital Private Equity
Change language